Development and Validation of a UPLC Method for Determination of Mirabegron in Tablet Dosage Forms
Journal of Pharmaceutical Research International,
Page 12-18
DOI:
10.9734/jpri/2022/v34i42B36299
Abstract
Mirabegron is a drug that is used to treat an overactive bladder. Mirabegron activates the β3 adrenergic receptor in the bladder's detrusor muscle, causing muscular relaxation and bladder capacity expansion. A few measurement procedures have been discovered, but they are inconvenient and time-consuming. The current study developed a simple, exact, precise, and practical UPLC technique for determining the amount of Mirabegron in tablet dosage forms. For the verification of Mirabegron, a simple and specific UPLC approach is applied. On an Acquity BEH C18 (50*3.0mm. 1.7m), chromatographic separation was achieved using a versatile stage containing Potassium di hydrogen phosphate: Methanol(70:30) v/v with a detection wavelength of 254 nm. Mirabegron (r2 = 0.997) showed linearity in the 50-150 g/ml range. The amount of Mirabegron to be employed by the suggested technique matches the label exactly. The proposed technique was validated according to ICH guidelines and used to ensure that the correct amount of medication was present in the dosage form.
Keywords:
- UPLC
- Mirabegron
- potassium di hydrogen phosphate
- methanol
How to Cite
References
Sunil Junapudi, Ramreddy Godela et.al Method development and validation for simultaneous estimation of dasatinib and lenvatinib by using rp-hplc in pharmaceutical dosage form.
Prashanthi Y, Mohammed Asif Ahmed, K. Vijaya, Riyazuddin et al. Method development and validation of lenvatinib drug by rp-hplc in pharmaceutical drug dosage form.
Junapudi Sunil et al. Method Development and Validation for Simultaneous Estimation of Dasatinib and Lenvatinib by Using UPLC in Pharmaceutical Dosage Form.
Khalid A et al: development and validation of a UPLC method for quantification of antiviral agent, acyclovir in lipid based formulations. Arabian journal of chemistry. 2019;12(7):1707-1714.
Amira H, et al. Spectrophotometric and robust UPLC methods for determination of velpatasvir and sofosbuvir in their tablet. Microchemical Journal. 2019;149:103996.
Susmita AG, Rajitha G. Development and validation of stability indicating UPLC method for simultaneous estimation of sofosbuvir and velpatasvir in tablet dosage form, international Journal of Pharmaceutical sciences and research. 2018;9.
Priyanka K, et al. A stability indicating RP-HPLC method for simultaneous estimation of velpatasvir and sofosbuvir in its bulk and tablet dosage form, Am. J. Pharm. Tech. Res. 2018;129–139
Mohammed A Othman, et al. Stability indicating HPLC method development and validation for determination of Daclatasvir in pure and tablets dosage forms., Indo American journal of pharmaceutical sciences. 2016;3(12).
Naser F. Al-tannak, et al. Development of a robust UPLCmethod for simultaneous determination of a novel combination of sofosbuvir and dacltasvir inhuman plasma: clinical application to therapeutic drug monitoring. Int. J of Anal Chem; 2018.
Magdy Atef Wadie at al. Development and Validation of a new, simple-HPLC method for simultaneous determination of sofosbuvir, daclatasvir and ribavirin in tablet dosage form. IOSR-JPBS. 2017;12(5):60-68.
Chatwal RG, Anand KS. High performance liquid chromatography. Instrumental methods of chemical analysis, 5thed.; Himalaya publishers: Mumbai. 2010;2.570-2.629.
Sarat M, et al. A novel stability‐indicating Ultra high‐performance liquid chromatography (UPLC) method has been developed and validated for the simultaneous estimation of Abacavir sulphate and Lamivudine in the capsule dosage form; 2012.
Vaijanath G, et al. Development and validation of UPLC method for determination of primaquine phosphate and its impurities. Journal of Pharmaceutical and biomedical analysis. 2008;46(2):236-242.
Abdel hamid, et al. UPLC assay for cinnarizine in lipid based formulations. Asian Journal of chemistry. 2012;24:595-600.
Belal TS, et al. New simple spectrophotometric method for determination of the binary mixtures (atorvastatin calcium and ezetimibe; candesartan cilexetil and hydrochlorothiazide) in tablets, J. Pharm. Anal. 2013;3:118–126.
ICH, Validation of Analytical Procedures: Methodology, ICH – Q2B, International Conference on Harmonisation. 1996;1-3.
ICH Guidelines, Q2 (R1) - Validation of Analytical Procedures:Text and Methodology. 2005;1-6.
-
Abstract View: 77 times
PDF Download: 19 times
